Pulse Biosciences COO Liane Teplitsky buys $99,971 in stock

Liane Rae Teplitsky, Chief Operating Officer at PULSE BIOSCIENCES, INC. (NASDAQ:PLSE), recently acquired company common stock totaling $99,971 through open market purchases. The transactions occurred over two days, with prices ranging from $48.80 to $49.95 per share.

On August 31, 2026, Ms. Teplitsky purchased 1,024 shares of common stock at a weighted average price of $48.80 per share. These shares were acquired in a series of open market transactions, with prices for individual shares ranging from $48.76 to $48.80.

The following day, September 1, 2026, Ms. Teplitsky acquired an additional 1,001 shares of common stock at a price of $49.95 per share. These purchases were executed through a broker-dealer as open market transactions.The insider purchases come as PLSE stock trades at $52.68, near its 52-week high of $54.39, following a remarkable 284% year-to-date surge. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value. The platform reveals 18 additional ProTips for PLSE, including insights on the company’s financial health and momentum indicators, available in the comprehensive Pro Research Report.

The company noted that all shares were purchased during an open trading window and in accordance with applicable securities laws. Following these transactions, Ms. Teplitsky beneficially owns 4,095 shares of PULSE BIOSCIENCES, INC. common stock, valued at approximately $216,000 at current market prices.

In other recent news, Pulse Biosciences reported a wider-than-expected loss for the second quarter of 2026, with an adjusted loss of $0.36 per share, missing Wall Street’s expectation of a $0.28 loss. The company’s revenue also fell short of forecasts, coming in at $400,000 compared to the anticipated $600,000. Despite these misses, the company noted progress in its pivotal atrial fibrillation trial and improvements in its thyroid and surgical programs. Additionally, Pulse Biosciences has been making strides in its clinical and regulatory efforts, as highlighted by Canaccord, which raised its price target for the company from $32 to $43 while maintaining a Buy rating. Needham also initiated coverage on Pulse Biosciences with a Buy rating, setting a price target of $58, citing the company’s development of its next-generation pulse field ablation platform technology. These developments reflect ongoing advancements in the company’s nanosecond pulsed field ablation system.